Please try another search
For the three months ended 31 March 2016, Exiqon A/S revenues remained flat at DKR39M. Net loss totaled DKR2.1M vs. income of DKR29K. Revenues reflect Diagnostics segment increase of 21% to DKR1M, Rest of World segment increase of 54% to DKR7.8M, also reflect Life Sciences segment decrease of less than 1% to DKR38M, Europe segment decrease of 14% to DKR17M, North America segment decrease of less than 1% to DKR14.2M.
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Revenue | 39.04 | 46.62 | 38.36 | 38.02 |
Gross Profit | 25.08 | 28.35 | 23.44 | 24.84 |
Operating Income | -0.24 | 0.55 | 1.31 | 0.82 |
Net Income | -2.12 | 5.24 | 0.62 | 0.01 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Assets | 153.15 | 183.02 | 142.09 | 139.41 |
Total Liabilities | 68.85 | 96.88 | 61.98 | 60.11 |
Total Equity | 84.3 | 86.14 | 80.11 | 79.31 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -6.26 | 16.06 | 10.72 | 4.66 |
Cash From Investing Activities | -1.27 | -5.78 | -3.82 | -2.46 |
Cash From Financing Activities | -15.81 | 25.23 | -2.05 | -1.35 |
Net Change in Cash | -23.54 | 36.07 | 5.33 | 1.35 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review